VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Langer on Cost Analysis in the Treatment Decision

Corey J. Langer, MD
Published: Thursday, Oct 13, 2011

Corey J. Langer, MD, Professor of Medicine, Director, Thoracic Oncology, Abramson Cancer Center, University of Pennsylvania, explains that as a clinician he does not use cost as a decision factor. The care of the patient and their quality-of-life takes priority over the cost efficacy of a drug. The cost analysis should not be a determining factor for which therapeutic agent to give.

Corey J. Langer, MD, Professor of Medicine, Director, Thoracic Oncology, Abramson Cancer Center, University of Pennsylvania, explains that as a clinician he does not use cost as a decision factor. The care of the patient and their quality-of-life takes priority over the cost efficacy of a drug. The cost analysis should not be a determining factor for which therapeutic agent to give.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Bridging the Gaps Around Oncology Biosimilars: Assessing the Potential Impact of Emerging Agents to PracticeSep 29, 20181.5
Community Practice Connections: Oncology Best Practice™ Targeting Cell Cycle Progression: The Latest Advances on CDK4/6 Inhibition in Metastatic Breast CancerOct 31, 20181.0
Publication Bottom Border
Border Publication
x